Benjamin J. Hindson - 01 Nov 2021 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Signature
/s/ Eric S. Whitaker, as Attorney-in-Fact
Issuer symbol
TXG
Transactions as of
01 Nov 2021
Net transactions value
-$6,403,166
Form type
4
Filing time
03 Nov 2021, 19:12:12 UTC
Previous filing
05 Oct 2021
Next filing
24 Nov 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXG Class A Common Stock Options Exercise $51,569 +10,232 +22% $5.04* 57,349 01 Nov 2021 Direct F1
transaction TXG Class A Common Stock Options Exercise $360,862 +31,434 +55% $11.48* 88,783 01 Nov 2021 Direct F1
transaction TXG Class A Common Stock Sale $176,554 -1,100 -1.2% $160.50 87,683 01 Nov 2021 Direct F1, F2
transaction TXG Class A Common Stock Sale $243,091 -1,500 -1.7% $162.06 86,183 01 Nov 2021 Direct F1, F3
transaction TXG Class A Common Stock Sale $1,929,950 -11,829 -14% $163.15 74,354 01 Nov 2021 Direct F1, F4
transaction TXG Class A Common Stock Sale $3,953,296 -24,125 -32% $163.87 50,229 01 Nov 2021 Direct F1, F5
transaction TXG Class A Common Stock Sale $512,706 -3,112 -6.2% $164.75 47,117 01 Nov 2021 Direct F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXG Stock Option (right to buy) Options Exercise $0 -10,232 -17% $0.000000 50,884 01 Nov 2021 Class A Common Stock 10,232 $5.04 Direct F1, F7
transaction TXG Stock Option (right to buy) Options Exercise $0 -31,434 -31% $0.000000 68,566 01 Nov 2021 Class A Common Stock 31,434 $11.48 Direct F1, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades at prices ranging from $160.00 to $160.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $161.45 to $162.43. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 This transaction was executed in multiple trades at prices ranging from $162.48 to $163.475. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5 This transaction was executed in multiple trades at prices ranging from $163.48 to $164.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6 This transaction was executed in multiple trades at prices ranging from $164.50 to $165.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F7 This option, originally for 175,000 shares, of which 124,116 shares have been exercised, vested as to 1/48th of the shares on October 1, 2018 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
F8 This option, originally for 100,000 shares, of which 31,434 shares have been exercised, vested as to 1/48th of the shares on May 1, 2019 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Remarks:

Chief Scientific Officer and President